- Home
- VHC vs MRSN Comparison
VHC vs MRSN Comparison
Compare VHC & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VHC
- MRSN
- Stock Information
- Founded
- VHC 2005
- MRSN 2001
- Country
- VHC United States
- MRSN United States
- Employees
- VHC N/A
- MRSN N/A
- Industry
- VHC Multi-Sector Companies
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- VHC Miscellaneous
- MRSN Health Care
- Exchange
- VHC Nasdaq
- MRSN Nasdaq
- Market Cap
- VHC 35.7M
- MRSN 40.7M
- IPO Year
- VHC 1999
- MRSN 2017
- Fundamental
- Price
- VHC $12.33
- MRSN $0.29
- Analyst Decision
- VHC
- MRSN Strong Buy
- Analyst Count
- VHC 0
- MRSN 5
- Target Price
- VHC N/A
- MRSN $5.75
- AVG Volume (30 Days)
- VHC 30.6K
- MRSN 2.8M
- Earning Date
- VHC 08-13-2025
- MRSN 08-12-2025
- Dividend Yield
- VHC N/A
- MRSN N/A
- EPS Growth
- VHC N/A
- MRSN N/A
- EPS
- VHC N/A
- MRSN N/A
- Revenue
- VHC $3,000.00
- MRSN $34,006,000.00
- Revenue This Year
- VHC N/A
- MRSN N/A
- Revenue Next Year
- VHC N/A
- MRSN $1.30
- P/E Ratio
- VHC N/A
- MRSN N/A
- Revenue Growth
- VHC N/A
- MRSN N/A
- 52 Week Low
- VHC $3.68
- MRSN $0.26
- 52 Week High
- VHC $13.89
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- VHC 71.22
- MRSN 38.23
- Support Level
- VHC $10.07
- MRSN $0.27
- Resistance Level
- VHC $9.05
- MRSN $0.36
- Average True Range (ATR)
- VHC 1.19
- MRSN 0.03
- MACD
- VHC 0.37
- MRSN -0.01
- Stochastic Oscillator
- VHC 100.00
- MRSN 16.81
About VHC VirnetX Holding Corp
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.